Recent advances of targeting nicotinamide phosphoribosyltransferase (NAMPT) for cancer drug discovery.
|
| Abstract |
Nicotinamide phosphoribosyltransferase (NAMPT) is the rate-limiting enzyme for the biosynthesis of NAD+ in the salvage pathway. NAMPT is overexpressed in various cancers, associating with a poor prognosis and tumor progression. Beyond cancer metabolism, recent evidence unravels additional roles of NAMPT in cancer biology, including DNA repair machinery, crosstalk with oncogenic signaling pathways, cancer cell stemness, and immune responses. NAMPT is a promising therapeutic target for cancer. However, first-generation NAMPT inhibitors exhibited limited efficacy and dose-limiting toxicities in clinical trials. Multiple strategies are being exploited to improve their efficacy and minimize toxic-side effects. This review discusses the biomarkers predictive of response to NAMPT inhibitors, and summarizes the most significant advances in the evolution of structurally distinct NAMPT inhibitors, the manipulation of targeted delivery technologies via antibody-drug conjugates (ADCs), PhotoActivated ChemoTherapy (PACT) and the intratumoral delivery system, as well as the development and pharmacological outcomes of NAMPT degraders. Finally, a discussion of future perspectives and challenges in this area is also included.
|
|---|---|
| Authors | He Tang, Lin Wang, Tianyu Wang, Jiamei Yang, Shuai Zheng, Jun Tong, Sheng Jiang, Xiangyu Zhang, Kuojun Zhang |
| Journal | European journal of medicinal chemistry (Eur J Med Chem) Vol. 258 Pg. 115607 (Oct 05 2023) ISSN: 1768-3254 [Electronic] France |
| PMID | 37413882 (Publication Type: Journal Article, Review) |
| Copyright | Copyright © 2023 Elsevier Masson SAS. All rights reserved. |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!